Mylan open to deals to grow OTC offering
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Mylan has expressed an interest in acquisitions to grow its burgeoning OTC portfolio, as the firm presses ahead with its goal to reach US$2.0 billion (€1.6 billion) in annual sales by 2021.